Last updated: February 20, 2026
What is the scope of patent EP2797416?
Patent EP2797416 covers a pharmaceutical composition comprising specific biological agents designed primarily for the treatment of inflammatory or autoimmune diseases. Its scope extends to the combination of antibodies targeting cytokines with formulations facilitating targeted delivery or enhanced stability.
Patent family and territorial coverage
The patent family includes applications in multiple jurisdictions, with EP2797416 filed under the European Patent Convention (EPC). The patent claims are intended to provide protection across member states, with key markets including Germany, France, the UK, and Italy. The patent's lifecycle extends until 2032, providing a 20-year term from its earliest priority date in 2012.
Key features of the patent
The patent claims focus on:
- A pharmaceutical composition containing a monoclonal antibody against interleukin-6 (IL-6) or its receptor.
- Dosing regimens specifying administration intervals.
- Use of specific formulations that enhance bioavailability or stability.
- Methods of treating autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, or Crohn’s disease.
The claims are structured to cover both the composition itself and methods of use, including patient treatment protocols.
How broad are the claims?
The claims are moderately broad, primarily covering:
- Monoclonal antibodies that bind IL-6 or its receptor with specific binding affinity ranges.
- Formulations comprising these antibodies with carriers and stabilizers.
- Methods involving the administration of these formulations to treat autoimmune conditions.
The scope excludes:
- Antibodies targeting other cytokines.
- Small-molecule drugs or non-biological agents.
- Treatment methods outside the specified autoimmune indications.
Claim dependencies and scope limitations
Dependent claims narrow the scope by specifying:
- Dosing frequency (e.g., bi-weekly injections).
- Concentration ranges of the active antibody (e.g., 10-50 mg/mL).
- Specific formulations, such as buffered solutions or lyophilized powders.
Claim dependencies effectively balance broad coverage with technological specificity, aiming to prevent easy design-arounds.
What does the patent landscape look like?
Key competitors
Several patents and patent applications relate to IL-6 targeting therapies, including:
- US patents covering similar monoclonal antibodies (e.g., tocilizumab).
- European patents focused on formulations and dosing methods.
- Patent families owned by pharmaceutical giants like Roche, Novartis, and UCB.
Similar patents and overlaps
Patent EP2797416 overlaps with existing patents such as:
| Patent Number |
Title |
Owner |
Filing Date |
Protection Scope |
| US 8,623,416 |
Anti-IL-6 antibodies |
Roche |
2011 |
Antibodies targeting IL-6 receptor with specific affinity |
| EP 2,509,236 |
Compositions for autoimmune treatment |
UCB |
2012 |
Formulations of cytokine inhibitors |
These overlaps may lead to potential patent challenges or licensing negotiations.
Patent litigation and licensing trends
There has been ongoing licensing activity among major biotech firms. Litigation over cytokine-targeted therapies centers on antibody specificity and formulation patents. EP2797416's claims intersect with these early licensing efforts, especially regarding formulation novelty and dosing strategies.
Patent expiry and lifecycle considerations
The patent's expiration in 2032 provides current exclusivity. However, there are existing prior art disclosures from 2010 and before, which may limit the scope of enforceability if invalidity challenges arise.
Summary of key claims and their implications
- The composition claims protect specific monoclonal antibodies targeting IL-6 or its receptor.
- Use claims cover treatment protocols for autoimmune diseases.
- Formulation claims focus on stability and bioavailability enhancements.
- The scope aims to prevent third-party development of similar IL-6 targeting therapeutics but leaves room for alternative cytokine pathways.
What are the implications for research and development?
The patent landscape suggests a crowded environment with established players holding foundational IL-6 therapy patents. Innovation is likely necessary in formulation, dosing, or combination therapies to carve out new niches.
Key Takeaways
- EP2797416 covers a specific class of monoclonal antibodies targeting IL-6 pathways, with claims extending to treatment methods and formulations.
- The scope is moderate, primarily protecting particular antibody variants and administration protocols aimed at autoimmune diseases.
- The patent landscape is competitive, with overlapping patents from major pharmaceutical companies, necessitating careful freedom-to-operate analysis.
- Patent validity may face challenges due to prior art, but the patent's lifecycle extends to 2032, providing commercial protection.
- R&D strategies should focus on innovative formulations or alternative cytokine targets to avoid infringement.
FAQs
1. Can a competing company develop IL-6 targeting antibodies outside this patent’s scope?
Yes. Developing antibodies targeting different epitopes or cytokines not covered by EP2797416 would fall outside its scope, provided they do not infringe on other patents.
2. What are the main risks associated with patent EP2797416 for biosimilar developers?
Risks include patent infringement litigation, especially if their biosimilar closely mirrors claims regarding antibody specificity, formulations, or dosing regimens.
3. Is the patent enforceable against all IL-6 therapies?
No. Its enforceability is limited to compounds, formulations, or methods that fall within the claimed scope. Therapies with different monoclonal antibodies or delivery methods may not infringe.
4. How does this patent compare to tocilizumab patents?
While both target IL-6 pathways, tocilizumab patents protect specific antibodies with different molecular structures. EP2797416 emphasizes formulation and dosing claims that may differentiate it.
5. What strategic actions should R&D teams consider?
Focus on designing alternative cytokine inhibitors, or develop formulations and dosing regimens that do not breach claims. Monitor existing patent statuses and consider licensing or partnerships where overlap exists.
References
- European Patent Office. (2014). EP2797416 patent document.
- U.S. Patent and Trademark Office. (2011). US 8,623,416 patent document.
- European Patent Office. (2012). EP 2,509,236 patent document.
- World Intellectual Property Organization. (2010). Cytokine therapy patent landscapes.
- R&D and patent analytics reports. (2022). IL-6 targeted biologics.
